I 
115TH CONGRESS 
2D SESSION 
H. R. 6505 
To amend title XVIII of the Social Security Act to require the Secretary 
of Health and Human Services to negotiate prices of prescription drugs 
furnished under part D of the Medicare program. 
IN THE HOUSE OF REPRESENTATIVES 
JULY 25, 2018 
Mr. DOGGETT (for himself, Mr. WELCH, Mr. CUMMINGS, Mr. KHANNA, Ms. 
DELAURO, Ms. SCHAKOWSKY, Ms. KAPTUR, Mr. POCAN, Mr. GRIJALVA, 
Ms. ADAMS, Ms. BARRAGA´N, Ms. BASS, Mrs. BEATTY, Mr. BLU-
MENAUER, Ms. BONAMICI, Mr. CARTWRIGHT, Mr. CASTRO of Texas, Ms. 
JUDY CHU of California, Mr. CICILLINE, Ms. CLARKE of New York, Mr. 
CLEAVER, Mr. COHEN, Mr. CRIST, Mr. DEFAZIO, Mr. DESAULNIER, Mr. 
ELLISON, Mr. EVANS, Mr. GARAMENDI, Mr. GONZALEZ of Texas, Mr. AL 
GREEN of Texas, Mr. GUTIE´RREZ, Ms. HANABUSA, Mr. HASTINGS, Mr. 
HIGGINS of New York, Ms. JACKSON LEE, Ms. JAYAPAL, Ms. EDDIE 
BERNICE
JOHNSON
of Texas, Mr. JOHNSON
of Georgia, Mr. 
KRISHNAMOORTHI, Mr. LANGEVIN, Mr. LAWSON of Florida, Ms. LEE, 
Mr. LEVIN, Mr. LEWIS of Georgia, Mr. LOWENTHAL, Ms. MICHELLE 
LUJAN GRISHAM of New Mexico, Mrs. CAROLYN B. MALONEY of New 
York, Ms. MCCOLLUM, Mr. MCNERNEY, Ms. MOORE, Mr. NADLER, Mrs. 
NAPOLITANO, Mr. NOLAN, Ms. NORTON, Mr. PERLMUTTER, Ms. PIN-
GREE, Mr. RASKIN, Mr. RUPPERSBERGER, Mr. RYAN of Ohio, Mr. SAR-
BANES, Mr. SCOTT of Virginia, Ms. SHEA-PORTER, Mr. SHERMAN, Mr. 
TAKANO, Mr. THOMPSON of Mississippi, Ms. TITUS, Mr. VARGAS, Mr. 
VEASEY, Ms. VELA´ZQUEZ, Mr. VISCLOSKY, Ms. WASSERMAN SCHULTZ, 
Ms. MAXINE WATERS of California, Ms. WILSON of Florida, Mr. 
ESPAILLAT, Mr. PETERSON, Mr. DANNY K. DAVIS of Illinois, Mr. LAR-
SON of Connecticut, Mr. SERRANO, Mr. JEFFRIES, and Ms. FRANKEL of 
Florida) introduced the following bill; which was referred to the Com-
mittee on Energy and Commerce, and in addition to the Committee on 
Ways and Means, for a period to be subsequently determined by the 
Speaker, in each case for consideration of such provisions as fall within 
the jurisdiction of the committee concerned 
VerDate Sep 11 2014 
00:15 Aug 03, 2018
Jkt 079200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6652
E:\BILLS\H6505.IH
H6505
pbinns on DSK79D2C42PROD with BILLS
A BILL 
To amend title XVIII of the Social Security Act to require 
the Secretary of Health and Human Services to negotiate 
prices of prescription drugs furnished under part D of 
the Medicare program. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Medicare Negotiation 
and Competitive Licensing Act of 2018’’. 
SEC. 2. REQUIRING THE SECRETARY OF HEALTH AND 
HUMAN SERVICES TO NEGOTIATE PRICES OF 
PRESCRIPTION DRUGS FURNISHED UNDER 
PART D OF THE MEDICARE PROGRAM. 
Section 1860D–11 of the Social Security Act (42 
U.S.C. 1395w–111) is amended by striking subsection (i) 
and inserting the following new subsection: 
‘‘(i) NEGOTIATION OF LOWER DRUG PRICES.— 
‘‘(1) IN GENERAL.—Notwithstanding any other 
provision of law, the Secretary shall, for plan years 
beginning on or after the date of the enactment of 
this subsection, negotiate with pharmaceutical man-
ufacturers the prices (including discounts, rebates, 
and other price concessions) that may be charged to 
PDP sponsors and MA organizations during a nego-
tiated price period (as specified by the Secretary) for 
VerDate Sep 11 2014 
00:15 Aug 03, 2018
Jkt 079200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H6505.IH
H6505
pbinns on DSK79D2C42PROD with BILLS
covered part D drugs for part D eligible individuals 
who are enrolled under a prescription drug plan or 
under an MA–PD plan. In negotiating such prices 
under this section, the Secretary shall take into ac-
count the following factors: 
‘‘(A) The comparative clinical effectiveness 
and cost effectiveness, when available from an 
impartial source, of such drug. 
‘‘(B) The budgetary impact of providing 
coverage of such drug. 
‘‘(C) The number of similarly effective 
drugs or alternative treatment regimens for 
each approved use of such drug. 
‘‘(D) The associated financial burden on 
patients that utilize such drug. 
‘‘(E) The associated unmet patient need 
for such drug. 
‘‘(F) The total revenues from global sales 
obtained by the manufacturer for such drug. 
‘‘(2) FINALIZATION OF NEGOTIATED PRICE.— 
The negotiated price of each covered part D drug for 
a negotiated price period shall be finalized not later 
than 30 days before a PDP sponsor is required to 
submit information described in subsection (b)(2) 
VerDate Sep 11 2014 
00:15 Aug 03, 2018
Jkt 079200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H6505.IH
H6505
pbinns on DSK79D2C42PROD with BILLS